Literature DB >> 29789900

Associations of sensitive cardiac troponin-I with left ventricular morphology, function and prognosis in end-stage renal disease patients with preserved ejection fraction.

Kenichiro Otsuka1, Koki Nakanishi2, Kenei Shimada3, Haruo Nakamura4, Hitoshi Inanami4, Hiroki Nishioka4, Kohei Fujimoto4, Noriaki Kasayuki4, Minoru Yoshiyama3.   

Abstract

Sensitive cardiac troponin I (cTnI) predicts all-cause and cardiovascular mortality in various clinical settings. However, its clinical significance in hemodialysis (HD) patients with preserved left ventricular ejection fraction (LVEF) has not been fully elucidated. This study investigated the association of cTnI with LV morphology and function, and its long-term outcome in HD patients with preserved LVEF. This prospective study consists of 96 HD patients with preserved LVEF (69 ± 8 years and 63% male) who underwent two-dimensional echocardiographic examination and biomarker tests including cTnI, brain natriuretic peptide, and high-sensitive C-reactive protein. The primary endpoint was all-cause death and secondary endpoint was cardiovascular death. Factors independently associated with cTnI were systolic blood pressure (β = - 0.239, p = 0.011), heart rate (β = 0.216, p = 0.021), LV mass index (β = 0.231, p = 0.020), and E to e' ratio (β = 0.237, p = 0.016). During a mean follow-up of 3.6 years, primary and secondary endpoints were observed in 23 (24%) and 18 (19%) patients, respectively. In the multivariate Cox proportional hazard analysis, the upper cTnI tertile has significantly increased risk of all-cause mortality [hazard ratio (HR), 2.69; 95% confidence interval (CI), 1.139-6.386; p = 0.024] and that of cardiovascular death (HR, 4.56; 95% CI 2.021-16.968; p = 0.006) independent of echocardiographic measures and other serum biomarkers. In HD patients with preserved LVEF, serum cTnI levels were significantly associated with diastolic function and risk of mortality independent of echocardiographic variables and other biomarkers.

Entities:  

Keywords:  Diastolic function; Hemodialysis; Preserved left ventricular function; Prognosis; Troponin

Mesh:

Substances:

Year:  2018        PMID: 29789900     DOI: 10.1007/s00380-018-1192-7

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  35 in total

1.  K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.

Authors: 
Journal:  Am J Kidney Dis       Date:  2005-04       Impact factor: 8.860

2.  Daily dialyses decrease plasma levels of brain natriuretic peptide (BNP), a biomarker of left ventricular dysfunction.

Authors:  Ingegerd Odar-Cederlöf; Per Bjellerup; Amy Williams; Christopher R Blagg; Zbylut Twardowski; George Ting; Carl M Kjellstrand
Journal:  Hemodial Int       Date:  2006-10       Impact factor: 1.812

3.  Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T.

Authors:  R Sharma; D C Gaze; D Pellerin; R L Mehta; H Gregson; C P Streather; P O Collinson; S J D Brecker
Journal:  Heart       Date:  2005-10-10       Impact factor: 5.994

4.  Troponin I levels in asymptomatic patients on haemodialysis using a high-sensitivity assay.

Authors:  Neeraj Kumar; Michael F Michelis; Maria V DeVita; Georgia Panagopoulos; Jordan L Rosenstock
Journal:  Nephrol Dial Transplant       Date:  2010-07-23       Impact factor: 5.992

5.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.

Authors:  E M Antman; M J Tanasijevic; B Thompson; M Schactman; C H McCabe; C P Cannon; G A Fischer; A Y Fung; C Thompson; D Wybenga; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-31       Impact factor: 91.245

6.  Echocardiographic strain and mortality in Black Americans with end-stage renal disease on hemodialysis.

Authors:  Gregg S Pressman; Harish Raj Seetha Rammohan; Abel Romero-Corral; Peter Fumo; Vincent M Figueredo; John Gorcsan
Journal:  Am J Cardiol       Date:  2015-09-03       Impact factor: 2.778

7.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

8.  Association of NTproBNP and cTnI with outpatient sudden cardiac death in hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study.

Authors:  Rachel M Kruzan; Charles A Herzog; Aozhou Wu; Yingying Sang; Rulan S Parekh; Kunihiro Matsushita; Seungyoung Hwang; Alan Cheng; Josef Coresh; Neil R Powe; Tariq Shafi
Journal:  BMC Nephrol       Date:  2016-02-20       Impact factor: 2.388

9.  High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease.

Authors:  Ian Ford; Anoop S V Shah; Ruiqi Zhang; David A McAllister; Fiona E Strachan; Muriel Caslake; David E Newby; Chris J Packard; Nicholas L Mills
Journal:  J Am Coll Cardiol       Date:  2016-12-27       Impact factor: 24.094

10.  Serum Cardiac Troponin-I is Superior to Troponin-T as a Marker for Left Ventricular Dysfunction in Clinically Stable Patients with End-Stage Renal Disease.

Authors:  Maurits S Buiten; Mihály K de Bie; Joris I Rotmans; Friedo W Dekker; Marjolijn van Buren; Ton J Rabelink; Christa M Cobbaert; Martin J Schalij; Arnoud van der Laarse; J Wouter Jukema
Journal:  PLoS One       Date:  2015-08-03       Impact factor: 3.240

View more
  4 in total

1.  Ankle-brachial index, arterial stiffness, and biomarkers in the prediction of mortality and outcomes in patients with end-stage kidney disease.

Authors:  Kenichiro Otsuka; Koki Nakanishi; Kenei Shimada; Haruo Nakamura; Hitoshi Inanami; Hiroki Nishioka; Kohei Fujimoto; Noriaki Kasayuki; Minoru Yoshiyama
Journal:  Clin Cardiol       Date:  2019-04-30       Impact factor: 2.882

2.  Routinely measured cardiac troponin I and N-terminal pro-B-type natriuretic peptide as predictors of mortality in haemodialysis patients.

Authors:  Masahiro Eriguchi; Kazuhiko Tsuruya; Marcelo Lopes; Brian Bieber; Keith McCullough; Roberto Pecoits-Filho; Bruce Robinson; Ronald Pisoni; Eiichiro Kanda; Kunitoshi Iseki; Hideki Hirakata
Journal:  ESC Heart Fail       Date:  2022-01-13

Review 3.  Advances in Multimodality Cardiovascular Imaging in the Diagnosis of Heart Failure With Preserved Ejection Fraction.

Authors:  Alberico Del Torto; Andrea Igoren Guaricci; Francesca Pomarico; Marco Guglielmo; Laura Fusini; Francesco Monitillo; Daniela Santoro; Monica Vannini; Alexia Rossi; Giuseppe Muscogiuri; Andrea Baggiano; Gianluca Pontone
Journal:  Front Cardiovasc Med       Date:  2022-03-09

Review 4.  Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Authors:  Ishan Lakhani; Michelle Vangi Wong; Joshua Kai Fung Hung; Mengqi Gong; Khalid Bin Waleed; Yunlong Xia; Sharen Lee; Leonardo Roever; Tong Liu; Gary Tse; Keith Sai Kit Leung; Ka Hou Christien Li
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.